About Takeda Pharmaceuticals
Takeda Pharmaceuticals is a company based in Dublin (Ireland) founded in 1986 was acquired by Takeda in May 2018. It operates as a Direct-to-Consumer (D2C) and Professional Services. Takeda Pharmaceuticals has raised $17 million across 2 funding rounds from investors including Takeda Pharmaceuticals. Takeda Pharmaceuticals has completed 16 acquisitions, including Advanced BioHealing, Baxalta and Bikam Pharmaceuticals. Takeda Pharmaceuticals offers products and services including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines. Takeda Pharmaceuticals operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Dublin, Ireland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Takeda Pharmaceutical Company Limited
- Date of Incorporation 22 Sep, 2017
- Jurisdiction Gurgaon, Haryana, India
-
Annual Revenue
$1.68 M (USD)24.41as on Mar 31, 2022
-
Net Profit
$5.02 K (USD)4.94as on Mar 31, 2022
-
EBITDA
-$375.83 K (USD)-158.6as on Mar 31, 2022
-
Total Equity Funding
$17 M (USD)
in 2 rounds
-
Latest Funding Round
$15 M (USD), Series B
Oct 30, 2013
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Advanced BioHealing
& 15 more
-
Acquired by
Takeda
(May 12, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Takeda Pharmaceuticals
Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines.
Developed for treating Narcolepsy Type 1 patients.
Innovated for rare and complex chronic diseases.
Created to address global infectious disease needs.
People of Takeda Pharmaceuticals
Unlock access to complete
Unlock access to complete
Software Development Team
330 people
Leadership Team
187 people
Data Analysis and Operations Team
65 people
Operations Team
60 people
Head Team
47 people
Legal and Compliance
43 people
Human Resources and Administration
42 people
Product Management Team
40 people
Unlock access to complete
Funding Insights of Takeda Pharmaceuticals
Takeda Pharmaceuticals has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Takeda Pharmaceuticals
Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Locked | Locked | Locked |
Investor details for Takeda Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takeda Pharmaceuticals
Takeda Pharmaceuticals has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Advanced BioHealing, Baxalta and Bikam Pharmaceuticals.
Investment portfolio details for Takeda Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of therapies for orphan diseases and other disease conditions
|
Locked | Locked | 2015 | Locked | |
|
Passionately pursuing better treatments for adults and children with rare liver diseases.
|
Locked | Locked | 2011 | Locked | |
|
Recombinant collagen technology is developed for chronic wound healing treatments.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Takeda Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Takeda Pharmaceuticals
Detailed financials for Takeda Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Takeda Pharmaceuticals Comparisons
Peer comparison for Takeda Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Takeda Pharmaceuticals
Takeda Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Detailed competitors of Takeda Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Takeda Pharmaceuticals
Complete news archive for Takeda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takeda Pharmaceuticals
Takeda Pharmaceuticals was founded in 1986 and raised its 1st funding round 25 years after it was founded.
Takeda Pharmaceuticals is headquartered in Dublin, Ireland.
Takeda Pharmaceuticals is a funded company, having raised a total of $17M across 2 funding rounds to date.
Annual revenue of Takeda Pharmaceuticals is $1.68M as on Mar 31, 2022.
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. The company focuses on areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs across various sectors, aiming to improve health outcomes and transform lives worldwide. Operations span multiple countries, ensuring a broad impact on global health systems.
Takeda Pharmaceuticals's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Takeda Pharmaceuticals offers Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines.
Takeda Pharmaceuticals has made 16 acquisitions, including Advanced BioHealing, Baxalta, and Bikam Pharmaceuticals.
Takeda Pharmaceuticals has 1 investor. Key investors include Takeda Pharmaceuticals.